SG10201602857UA - NAMPT And Rock Inhibitors - Google Patents
NAMPT And Rock InhibitorsInfo
- Publication number
- SG10201602857UA SG10201602857UA SG10201602857UA SG10201602857UA SG10201602857UA SG 10201602857U A SG10201602857U A SG 10201602857UA SG 10201602857U A SG10201602857U A SG 10201602857UA SG 10201602857U A SG10201602857U A SG 10201602857UA SG 10201602857U A SG10201602857U A SG 10201602857UA
- Authority
- SG
- Singapore
- Prior art keywords
- nampt
- rock inhibitors
- rock
- inhibitors
- Prior art date
Links
- 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 title 1
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000011435 rock Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41372210P | 2010-11-15 | 2010-11-15 | |
US201161474015P | 2011-04-11 | 2011-04-11 | |
US201161525405P | 2011-08-19 | 2011-08-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201602857UA true SG10201602857UA (en) | 2016-05-30 |
Family
ID=45034200
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202010119TA SG10202010119TA (en) | 2010-11-15 | 2011-11-11 | NAMPT And Rock Inhibitors |
SG2013037643A SG190819A1 (en) | 2010-11-15 | 2011-11-11 | Nampt and rock inhibitors |
SG10201602857UA SG10201602857UA (en) | 2010-11-15 | 2011-11-11 | NAMPT And Rock Inhibitors |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202010119TA SG10202010119TA (en) | 2010-11-15 | 2011-11-11 | NAMPT And Rock Inhibitors |
SG2013037643A SG190819A1 (en) | 2010-11-15 | 2011-11-11 | Nampt and rock inhibitors |
Country Status (23)
Country | Link |
---|---|
US (2) | US9302989B2 (en) |
EP (1) | EP2640698A1 (en) |
JP (2) | JP6117104B2 (en) |
KR (1) | KR20140009251A (en) |
CN (1) | CN103313968A (en) |
AR (1) | AR083855A1 (en) |
AU (2) | AU2011329233A1 (en) |
BR (1) | BR112013012078A2 (en) |
CA (1) | CA2816594A1 (en) |
CL (1) | CL2013001340A1 (en) |
CO (1) | CO6761389A2 (en) |
CR (1) | CR20130267A (en) |
DO (1) | DOP2013000106A (en) |
EC (1) | ECSP13012993A (en) |
GT (1) | GT201300124A (en) |
IL (1) | IL225862A0 (en) |
MX (1) | MX2013005454A (en) |
PE (1) | PE20140913A1 (en) |
RU (1) | RU2013126657A (en) |
SG (3) | SG10202010119TA (en) |
TW (1) | TW201238950A (en) |
UY (1) | UY33726A (en) |
WO (1) | WO2012067965A1 (en) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
MX2013005454A (en) * | 2010-11-15 | 2013-06-24 | Abbvie Inc | Nampt and rock inhibitors. |
CA2817165A1 (en) | 2010-11-15 | 2012-05-24 | Patrick Chaltin | Novel antiviral compounds |
GB201021103D0 (en) * | 2010-12-13 | 2011-01-26 | Univ Leuven Kath | New compounds for the treatment of neurodegenerative diseases |
AR082889A1 (en) | 2011-05-09 | 2013-01-16 | Forma Therapeutics Inc | COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT |
US9199981B2 (en) * | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
ES2761332T3 (en) * | 2011-09-01 | 2020-05-19 | Novartis Ag | Compounds and compositions as c-kit kinase inhibitors |
MX348311B (en) * | 2011-11-11 | 2017-06-06 | Abbvie Inc | Nampt inhibitors. |
ES2672367T3 (en) * | 2012-01-09 | 2018-06-14 | X-Chem, Inc. | Triptoline derivatives that have kinase inhibitory activity and their uses |
JP5925723B2 (en) * | 2012-04-13 | 2016-05-25 | 田辺三菱製薬株式会社 | Pharmaceutical use of amide derivatives |
RU2015106013A (en) * | 2012-08-10 | 2016-10-10 | Ф. Хоффманн-Ля Рош Аг | Compounds of pyrazolecarboxamide, compositions and methods of use |
EA201500362A1 (en) | 2012-10-05 | 2015-08-31 | Кадмон Корпорейшн, Ллк | RHO-KINASE INHIBITORS |
WO2014074715A1 (en) * | 2012-11-07 | 2014-05-15 | Genentech, Inc. | Cyclopropyl amide derivatives |
CA2898440A1 (en) * | 2013-01-18 | 2014-07-24 | Bristol-Myers Squibb Company | Phthalazinones and isoquinolinones as rock inhibitors |
WO2014141035A2 (en) * | 2013-03-11 | 2014-09-18 | Aurigene Discovery Technologies Limited | Fused heterocyclyl derivatives as nampt inhibitors |
PT2968316T (en) | 2013-03-13 | 2019-10-29 | Forma Therapeutics Inc | 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer |
WO2015142001A2 (en) * | 2014-03-21 | 2015-09-24 | 충남대학교산학협력단 | Compound having cardiotonic activity and pharmaceutical composition for preventing or treating heart failure, containing same |
US9902702B2 (en) | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
SG11201700039TA (en) | 2014-07-23 | 2017-02-27 | Aurigene Discovery Tech Ltd | 4,5-dihydroisoxazole derivatives as nampt inhibitors |
US9673344B2 (en) * | 2014-08-07 | 2017-06-06 | Lumeta, Llc | Apparatus and method for photovoltaic module with tapered edge seal |
ES2838573T3 (en) | 2014-08-21 | 2021-07-02 | Bristol Myers Squibb Co | Benzamide derivatives linked as potent ROCK inhibitors |
EP3549582A3 (en) * | 2014-08-29 | 2020-01-01 | The Board of Regents of The University of Texas System | Novel capsazepine analogs for the treatment of cancer and other proliferative diseases |
US20160108406A1 (en) * | 2014-10-08 | 2016-04-21 | University Of Iowa Research Foundation | Method of regulating cftr expression and processing |
CN106928252B (en) * | 2015-12-31 | 2019-09-27 | 成都先导药物开发股份有限公司 | A kind of compound and the preparation method and application thereof inhibiting ROCK |
TWI730032B (en) | 2016-01-13 | 2021-06-11 | 美商必治妥美雅史谷比公司 | Spiroheptane salicylamides and related compounds as inhibitors of rock |
JP7010834B2 (en) * | 2016-03-17 | 2022-02-10 | チェックメイト セラピューティクス インコーポレイテッド | A novel compound for suppressing nicotinamide phosphoribosyltransferase and a composition containing the same. |
EP3438109B1 (en) * | 2016-03-31 | 2021-08-25 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
EP3872078A1 (en) | 2016-07-01 | 2021-09-01 | Pfizer Inc. | 5,7-dihydro-pyrrolo-pyridine derivatives for use in the treament of depression, anxiety or panic disorders |
CN109661396B (en) | 2016-07-07 | 2022-07-01 | 百时美施贵宝公司 | Spiro-fused cyclic ureas as ROCK inhibitors |
CN109843334A (en) | 2016-10-18 | 2019-06-04 | 西雅图基因公司 | The targeted delivery of nicotinamide adenine dinucleotide remedial pathway inhibitor |
WO2018086703A1 (en) | 2016-11-11 | 2018-05-17 | Bayer Pharma Aktiengesellschaft | Dihydropyridazinones substituted with phenylureas |
CN110382481A (en) * | 2016-11-21 | 2019-10-25 | 转化药物开发有限责任公司 | Heterocyclic compound as kinase inhibitor |
CA3060080C (en) | 2017-04-14 | 2024-01-23 | The United States Of America As Represented By The Department Of Veterans Affairs | Compositions and methods for treating pulmonary fibrosis |
US10975167B2 (en) | 2017-04-14 | 2021-04-13 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Method to reduce pulmonary arterial hypertension by administering inhibitors of nicotinamide phosphoribotransferase |
TW201904613A (en) | 2017-04-27 | 2019-02-01 | 美商西雅圖遺傳學公司 | Quaternary alkalization nicotine indoleamine dinucleotide salvage synthetic inhibitor conjugate |
EP3642202B1 (en) | 2017-06-22 | 2022-11-02 | Pfizer Inc. | Dihydro-pyrrolo-pyridine derivatives |
CN107118157A (en) * | 2017-06-23 | 2017-09-01 | 南京大学 | The design and synthesis of diphenyl urea analog derivative antitumoral compounds of one class containing pyrazol framework |
CN110914257B (en) | 2017-07-12 | 2023-05-26 | 百时美施贵宝公司 | Spiroheptylhydantoins as ROCK inhibitors |
TW201908293A (en) | 2017-07-12 | 2019-03-01 | 美商必治妥美雅史谷比公司 | 5 members of ROCK inhibitor and bicyclic heterocyclic guanamine |
ES2894128T3 (en) | 2017-07-12 | 2022-02-11 | Bristol Myers Squibb Co | ROCK 5,6- or 6,6-membered bicyclic aminoheterocyclic and 5-membered aminoheterocyclic inhibitors for the treatment of heart failure |
KR20200028424A (en) | 2017-07-12 | 2020-03-16 | 브리스톨-마이어스 스큅 컴퍼니 | Phenylacetamide as ROCK inhibitor |
US11319295B2 (en) * | 2017-10-09 | 2022-05-03 | Merck Sharp & Dohme Corp. | Substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
EP3746079A1 (en) * | 2018-01-31 | 2020-12-09 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
HU231223B1 (en) | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | Bicyclic derivatives as gabaa a5 receptor modulators |
CN113382633A (en) | 2018-10-29 | 2021-09-10 | 福马治疗股份有限公司 | Solid forms of (4- (2-fluoro-4- (1-methyl-1H-benzo [ d ] imidazol-5-yl) benzoyl) piperazin-1-yl) (1-hydroxycyclopropyl) methanone |
RU2732297C2 (en) * | 2018-11-14 | 2020-09-15 | Общество с ограниченной ответственностью "Гурус БиоФарм" | Derivatives of non-steroid anti-inflammatory agents |
WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
EP4211171A2 (en) | 2020-09-10 | 2023-07-19 | Precirix N.V. | Antibody fragment against fap |
WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
WO2023245470A1 (en) * | 2022-06-22 | 2023-12-28 | 南方医科大学珠江医院 | Use of mdp analog in preparing medicament for treating inflammatory bowel disease |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH433312A (en) * | 1963-10-18 | 1967-04-15 | Dresden Arzneimittel | Process for the preparation of therapeutically valuable amides of isoindoline-2-carboxylic acid |
CH443312A (en) * | 1963-10-29 | 1967-09-15 | Ajinomoto Kk | Process for the preparation of 1-N-oxide of hypoxanthine and 1-N-oxide of inosine, substituted or not, and use of the products obtained by this process for the use of the products obtained by this process for the preparation of 2,6- dichloropurine and 9-BD-ribofuranosyl purine, substituted or not |
GB1029326A (en) | 1964-03-18 | 1966-05-11 | Dresden Arzneimittel | Isoindoline-2-carboxylic acid amides |
BE648616A (en) | 1964-05-29 | 1964-09-16 | Dresden Arzneimittel | Amides of isoindolin-2-carboxylic acids and their preparation process. |
US4419360A (en) | 1979-10-31 | 1983-12-06 | Rohm And Haas Company | Arthropod repellants |
YU183090A (en) | 1990-09-27 | 1992-12-21 | Lek | NEW N-ACYLDIPEPTIDES, PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM |
US5726197A (en) * | 1992-11-02 | 1998-03-10 | Syntex (U.S.A.) Inc. | Isoindolinyl derivatives |
MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
WO1996024587A1 (en) | 1995-02-09 | 1996-08-15 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
FR2733750B1 (en) | 1995-05-03 | 1997-06-13 | Synthelabo | DERIVATIVES OF GAMMA-OXO-ALPHA- (PHENYLMETHYL) -5,6- DIHYDRO-4H-THIENO (3,4-C) PYRROLE-5-BUTANOIQUE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
JPH11512429A (en) | 1995-09-15 | 1999-10-26 | ファルマシア・アンド・アップジョン・カンパニー | Aminoaryloxazolidinone N-oxide |
DE19624659A1 (en) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | New pyridylalkene and pyridylalkanoic acid amides |
DE19624668A1 (en) | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Use of pyridylalkane, pyridylalken or pyridylalkynamides |
US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
KR20010101675A (en) | 1999-01-26 | 2001-11-14 | 우에노 도시오 | 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient |
GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
EP1343796A4 (en) | 2000-10-23 | 2005-01-12 | Smithkline Beecham Corp | Compounds and methods |
EP1385823B1 (en) | 2001-04-09 | 2006-12-13 | Chiron Corporation | Guanidino compounds as melanocortin-4 receptor (mc4-r) agonists |
US6649606B1 (en) | 2001-11-09 | 2003-11-18 | Bristol-Myers Squibb Co. | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
JP2003277340A (en) | 2002-03-22 | 2003-10-02 | Toray Ind Inc | Adhesive molecule inhibitor and new amino acid derivative |
EP1348434A1 (en) | 2002-03-27 | 2003-10-01 | Fujisawa Deutschland GmbH | Use of pyridyl amides as inhibitors of angiogenesis |
WO2004046107A1 (en) | 2002-11-19 | 2004-06-03 | Takeda Pharmaceutical Company Limited | Indole derivatives as somatostatin agonists or antagonists |
CN100434420C (en) | 2003-01-31 | 2008-11-19 | 株式会社三和化学研究所 | Compound inhibiting dipeptidyl peptidase iv |
WO2004101533A1 (en) | 2003-05-12 | 2004-11-25 | Janssen Pharmaceutica, N.V. | 1, 3, 4-benzotriazepin-2-one salts and their use as cck receptor ligands |
GB0310865D0 (en) | 2003-05-12 | 2003-06-18 | Black James Foundation | Gastrin and cholecystokinin receptor ligands |
WO2005005392A1 (en) | 2003-07-07 | 2005-01-20 | Ionix Pharmaceuticals Limited | Azacyclic compounds as inhibitors of sensory neurone specific channels |
CA2900181C (en) | 2003-08-06 | 2019-01-29 | Catherine Tachdjian | Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof |
WO2005019240A2 (en) | 2003-08-13 | 2005-03-03 | Amgen, Inc. | Melanin concentrating hormone receptor antagonists |
AP2287A (en) | 2003-10-14 | 2011-10-31 | Intermune Inc | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication. |
WO2005051945A1 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Heterocyclic compounds as modulators of peroxisome proliferator activated receptors, useful for the treatment and/or prevention of disorders modulated by a ppar |
GB0329214D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
AU2005228894B9 (en) | 2004-03-30 | 2011-10-13 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
DE602004009344T2 (en) | 2004-04-19 | 2008-07-10 | Symed Labs Ltd., Hyderabad | A NEW METHOD FOR THE PRODUCTION OF LINEZOLID AND RELATED COMPOUNDS |
EP1768967B1 (en) | 2004-07-20 | 2009-04-22 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
US20060045953A1 (en) * | 2004-08-06 | 2006-03-02 | Catherine Tachdjian | Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers |
JP2008514702A (en) | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | Novel cyclosporine analogues and their pharmaceutical use |
ES2314744T3 (en) | 2004-12-16 | 2009-03-16 | F. Hoffmann-La Roche Ag | PIPERAZINYLPIRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS. |
US8110573B2 (en) * | 2004-12-30 | 2012-02-07 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases |
BRPI0610850A2 (en) * | 2005-04-19 | 2008-12-02 | Bayer Pharmaceuticals Corp | Aryl alkyl acid derivatives, pharmaceutical composition, medicament as well as use of said derivatives |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
WO2007011290A1 (en) | 2005-07-18 | 2007-01-25 | Respiratorius Ab | Bronchorelaxing agents based on indol- and isoquinoline derivatives |
JP5212101B2 (en) | 2005-09-02 | 2013-06-19 | アステラス製薬株式会社 | New compounds |
US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
KR20080067697A (en) | 2005-11-11 | 2008-07-21 | 에프. 호프만-라 로슈 아게 | Carbocyclic fused cyclic amines as inhibitors of the coagulation factor xa |
WO2007076055A2 (en) | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
JP4012239B2 (en) * | 2006-01-11 | 2007-11-21 | 生化学工業株式会社 | Oxazolone derivatives |
JP4047365B2 (en) * | 2006-01-11 | 2008-02-13 | 生化学工業株式会社 | Cycloalkanecarboxamide derivative and method for producing the same |
CN101374825A (en) * | 2006-01-13 | 2009-02-25 | 霍夫曼-拉罗奇有限公司 | Cyclohexyl piperazinyl methanone derivatives and their use as histamine h3 receptor modulators |
CA2640807A1 (en) * | 2006-02-17 | 2007-08-23 | F. Hoffmann-La Roche Ag | Benzoyl-piperidine derivatives as 5ht2/d3 modulators |
WO2007121124A2 (en) * | 2006-04-11 | 2007-10-25 | Novartis Ag | Hcv inhibitors comprising beta amino acids and their uses |
ES2536762T3 (en) | 2006-05-18 | 2015-05-28 | Arena Pharmaceuticals, Inc. | Primary amines and their derivatives as 5-HT2A serotonin receptor modulators useful for the treatment of disorders related to this |
CA2651769C (en) | 2006-05-18 | 2013-12-17 | F. Hoffmann-La Roche Ag | Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists |
KR20090015098A (en) | 2006-05-30 | 2009-02-11 | 에프. 호프만-라 로슈 아게 | Piperidinyl pyrimidine derivatives |
WO2008027740A2 (en) | 2006-08-29 | 2008-03-06 | Office Of Intellectual Property And Technology | Catalytic asymmetric synthesis of primary amines via borane reduction of oxime ethers using spiroborate esters |
WO2008026018A1 (en) | 2006-09-01 | 2008-03-06 | Topotarget Switzerland Sa | New method for the treatment of inflammatory diseases |
US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
CL2007003874A1 (en) * | 2007-01-03 | 2008-05-16 | Boehringer Ingelheim Int | COMPOUNDS DERIVED FROM BENZAMIDA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT CARDIOVASCULAR DISEASES, HYPERTENSION, ATEROSCLEROSIS, RESTENOSIS, ICTUS, HEART FAILURE, ISCHEMICAL INJURY, HYPERTENSION |
CA2676944C (en) | 2007-02-15 | 2016-01-19 | F. Hoffmann-La Roche Ag | 2-aminooxazolines as taar1 ligands |
EP2137158A4 (en) | 2007-02-28 | 2012-04-18 | Methylgene Inc | Small molecule inhibitors of protein arginine methyltransferases (prmts) |
GB0705882D0 (en) | 2007-03-27 | 2007-05-02 | Glaxo Group Ltd | Novel compounds |
BRPI0810362A2 (en) | 2007-04-19 | 2014-10-29 | Concert Pharmaceuticals Inc | DEFERRED MORPHOLINYL COMPOUNDS |
WO2008130319A2 (en) | 2007-04-23 | 2008-10-30 | Astrazeneca Ab | Novel n-tetrahydronaphtalene or n-chromane carboxamide derivatives for the treatment of pain |
US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
EP2209774A1 (en) | 2007-10-02 | 2010-07-28 | Concert Pharmaceuticals Inc. | Pyrimidinedione derivatives |
EP2215058B1 (en) | 2007-10-17 | 2011-11-23 | Sanofi | Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof |
EP2212298B1 (en) | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
CA2703591C (en) | 2007-10-26 | 2013-05-07 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
GB0721332D0 (en) | 2007-10-31 | 2007-12-12 | Motac Neuroscience Ltd | Medicaments |
EP2067771A1 (en) | 2007-12-03 | 2009-06-10 | EPFL Ecole Polytechnique Fédérale de Lausanne | Derivatives of Dihydroxypyrrolidine as Anti-Cancer Compounds |
MX2010006216A (en) | 2007-12-05 | 2010-08-02 | Astrazeneca Ab | New compounds iii. |
WO2009086835A1 (en) | 2008-01-11 | 2009-07-16 | Topotarget A/S | Novel cyanoguanidines |
JP2011088826A (en) * | 2008-01-31 | 2011-05-06 | Astellas Pharma Inc | Aromatic carboxylic acid compound |
EP2098231A1 (en) | 2008-03-05 | 2009-09-09 | Topotarget Switzerland SA | Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury |
WO2009118712A2 (en) | 2008-03-27 | 2009-10-01 | Ecole Polytechnique Federale De Lausanne (Epfl) | Novel dihydroxypyrrolidine derivatives as anti-cancer agents |
MX2010014310A (en) | 2008-06-24 | 2011-02-15 | Topotarget As | Squaric acid derivatives as inhibitors of the nicotinamide. |
EP2342181A1 (en) | 2008-08-29 | 2011-07-13 | Topo Target A/S | Novel urea and thiourea derivatives |
WO2010033349A1 (en) | 2008-09-16 | 2010-03-25 | Merck & Co., Inc. | Phthalimide derivative metabotropic glutamate r4 ligands |
WO2010045306A2 (en) | 2008-10-16 | 2010-04-22 | Schering Corporation | Azine derivatives and methods of use thereof |
WO2010057101A2 (en) | 2008-11-17 | 2010-05-20 | Schering Corporation | Compounds useful as hiv blockers |
WO2010066709A1 (en) | 2008-12-09 | 2010-06-17 | Topotarget A/S | Novel pyridinyl acrylamide derivatives |
TW201030007A (en) | 2009-02-06 | 2010-08-16 | Gruenenthal Gmbh | Substituted spiro-amides as b1r modulators |
WO2010122968A1 (en) | 2009-04-21 | 2010-10-28 | アステラス製薬株式会社 | Diacylethylenediamine compound |
WO2011006803A1 (en) | 2009-07-14 | 2011-01-20 | Nerviano Medical Sciences S.R.L. | 3-0x0-2, 3, -dihydro-lh-isoindole-4-carboxamides with selective parp-1 inhibition |
KR20130044382A (en) | 2010-03-01 | 2013-05-02 | 마이렉시스 인코포레이티드 | Compounds and therapeutic uses thereof |
KR20140020823A (en) | 2010-09-03 | 2014-02-19 | 포르마 티엠, 엘엘씨. | Guanidine compounds and compositions for the inhibition of nampt |
AU2011295724B2 (en) | 2010-09-03 | 2016-05-12 | Forma Tm, Llc | 4- { [ ( pyridin- 3 - yl -methyl) aminocarbonyl] amino} benzene - sulfone derivatives as NAMPT inhibitors for therapy of diseases such as cancer |
JP5881704B2 (en) | 2010-09-03 | 2016-03-09 | フォーマ ティーエム, エルエルシー. | Novel compounds and compositions for inhibition of NAMPT |
MX2013005454A (en) * | 2010-11-15 | 2013-06-24 | Abbvie Inc | Nampt and rock inhibitors. |
-
2011
- 2011-11-11 MX MX2013005454A patent/MX2013005454A/en unknown
- 2011-11-11 WO PCT/US2011/060425 patent/WO2012067965A1/en active Application Filing
- 2011-11-11 RU RU2013126657/04A patent/RU2013126657A/en not_active Application Discontinuation
- 2011-11-11 US US13/294,303 patent/US9302989B2/en active Active
- 2011-11-11 BR BR112013012078A patent/BR112013012078A2/en not_active IP Right Cessation
- 2011-11-11 UY UY0001033726A patent/UY33726A/en not_active Application Discontinuation
- 2011-11-11 AU AU2011329233A patent/AU2011329233A1/en not_active Abandoned
- 2011-11-11 CA CA2816594A patent/CA2816594A1/en not_active Abandoned
- 2011-11-11 PE PE2013001089A patent/PE20140913A1/en not_active Application Discontinuation
- 2011-11-11 KR KR1020137015348A patent/KR20140009251A/en not_active Application Discontinuation
- 2011-11-11 SG SG10202010119TA patent/SG10202010119TA/en unknown
- 2011-11-11 JP JP2013538943A patent/JP6117104B2/en active Active
- 2011-11-11 EP EP11787996.5A patent/EP2640698A1/en not_active Withdrawn
- 2011-11-11 SG SG2013037643A patent/SG190819A1/en unknown
- 2011-11-11 CN CN2011800647158A patent/CN103313968A/en active Pending
- 2011-11-11 SG SG10201602857UA patent/SG10201602857UA/en unknown
- 2011-11-11 AR ARP110104229A patent/AR083855A1/en unknown
- 2011-11-11 TW TW100141323A patent/TW201238950A/en unknown
-
2013
- 2013-04-21 IL IL225862A patent/IL225862A0/en unknown
- 2013-05-14 GT GT201300124A patent/GT201300124A/en unknown
- 2013-05-14 DO DO2013000106A patent/DOP2013000106A/en unknown
- 2013-05-14 CL CL2013001340A patent/CL2013001340A1/en unknown
- 2013-06-07 CR CR20130267A patent/CR20130267A/en unknown
- 2013-06-13 EC ECSP13012993 patent/ECSP13012993A/en unknown
- 2013-06-14 CO CO13143136A patent/CO6761389A2/en unknown
-
2015
- 2015-10-12 US US14/880,834 patent/US10093624B2/en active Active
-
2017
- 2017-01-06 AU AU2017200079A patent/AU2017200079A1/en not_active Abandoned
- 2017-03-22 JP JP2017055914A patent/JP2017132792A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2017200079A1 (en) | 2017-02-02 |
CL2013001340A1 (en) | 2013-09-06 |
DOP2013000106A (en) | 2013-10-15 |
UY33726A (en) | 2012-06-29 |
CR20130267A (en) | 2013-10-04 |
RU2013126657A (en) | 2014-12-27 |
US9302989B2 (en) | 2016-04-05 |
IL225862A0 (en) | 2013-06-27 |
CN103313968A (en) | 2013-09-18 |
AU2011329233A1 (en) | 2013-05-23 |
EP2640698A1 (en) | 2013-09-25 |
MX2013005454A (en) | 2013-06-24 |
AR083855A1 (en) | 2013-03-27 |
JP2013542265A (en) | 2013-11-21 |
JP2017132792A (en) | 2017-08-03 |
BR112013012078A2 (en) | 2019-09-24 |
KR20140009251A (en) | 2014-01-22 |
CO6761389A2 (en) | 2013-09-30 |
ECSP13012993A (en) | 2014-01-31 |
GT201300124A (en) | 2014-12-12 |
PE20140913A1 (en) | 2014-08-22 |
US20120122842A1 (en) | 2012-05-17 |
US20160031880A1 (en) | 2016-02-04 |
JP6117104B2 (en) | 2017-04-19 |
SG10202010119TA (en) | 2020-11-27 |
WO2012067965A1 (en) | 2012-05-24 |
TW201238950A (en) | 2012-10-01 |
SG190819A1 (en) | 2013-07-31 |
CA2816594A1 (en) | 2012-05-24 |
US10093624B2 (en) | 2018-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL225862A0 (en) | Nampt and rock inhibitors | |
HK1254345B (en) | Cdk inhibitors | |
EP2678018A4 (en) | Combination of kanase inhibitors and uses thereof | |
HK1198827A1 (en) | Dyrk1 inhibitors and uses thereof dyrk1 | |
ZA201206456B (en) | Uses of dgati inhibitors | |
GB201018996D0 (en) | Novel ROCK inhibitors | |
EP2776393A4 (en) | Nampt inhibitors | |
EP2563127A4 (en) | Prolylcarboxypeptidase inhibitors | |
ZA201109216B (en) | Rock anchor | |
EP2521451A4 (en) | Hedgehog inhibitors | |
ZA201401417B (en) | Novel soft rock inhibitors | |
ZA201307496B (en) | Novel rock inhibitors | |
EP2688901A4 (en) | INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10 | |
GB201114854D0 (en) | Novel rock inhibitors | |
HK1213550A1 (en) | Novel rock inhibitors rock | |
ZA201208111B (en) | Cytokine inhibitors | |
GB201003395D0 (en) | Novel rock inhibitors | |
GB201018597D0 (en) | Inhibitors | |
GB0913139D0 (en) | Soft rock inhibitors | |
GB0915447D0 (en) | Soft rock inhibitors |